Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Goodwill and Intangible Assets

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Goodwill and Intangible Asset Disclosure

Pfizer Inc., balance sheet: goodwill and intangible assets

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Developed technology rights
Brands
Licensing agreements and other
Finite-lived intangible assets, gross carrying amount
Accumulated amortization
Finite-lived intangible assets, net
Brands
IPR&D
Licensing agreements and other
Indefinite-lived intangible assets
Identifiable intangible assets
Goodwill
Identifiable intangible assets and goodwill

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The composition of intangible assets and goodwill exhibits significant changes over the five-year period. A substantial increase is observed in both finite-lived and indefinite-lived intangible assets, alongside a consistent rise in goodwill.

Finite-Lived Intangible Assets
The gross carrying amount of finite-lived intangible assets demonstrates a consistent upward trend, increasing from US$76,552 million in 2021 to US$104,006 million in 2025. Developed technology rights constitute the largest component of these assets, growing from US$73,346 million to US$100,630 million over the same period. Accumulated amortization also increased steadily, from -US$55,838 million to -US$72,496 million, reflecting the consumption of the economic benefits of these assets. Consequently, the net book value of finite-lived intangible assets increased significantly from US$20,714 million in 2021 to US$31,510 million in 2025, although a decrease is noted in 2024 to US$35,848 million.
Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets experienced a marked increase between 2021 and 2023, rising from US$4,432 million to US$24,784 million. This growth is primarily driven by increases in IPR&D and licensing agreements. A decrease is observed in 2024 to US$19,563 million, followed by a recovery to US$22,221 million in 2025. Brands also show an increase, particularly in 2024, reaching US$1,277 million before decreasing to US$1,035 million in 2025.
Goodwill
Goodwill increased consistently throughout the period, from US$49,208 million in 2021 to US$71,264 million in 2025. This suggests continued acquisitions or increased value assigned to existing reporting units. The rate of increase appears to moderate slightly between 2024 and 2025.
Total Intangible Assets and Goodwill
The combined value of identifiable intangible assets and goodwill demonstrates a substantial increase, rising from US$74,354 million in 2021 to US$124,995 million in 2025. A slight decrease is observed in 2024, falling to US$123,938 million, before recovering in the final year. This indicates a growing reliance on intangible assets and acquired goodwill in the company’s overall asset base.

The increases in intangible assets, particularly developed technology rights and IPR&D, suggest significant investment in research and development or acquisitions of technology-driven businesses. The consistent growth in goodwill warrants further investigation into the underlying acquisitions and the associated impairment risk assessments.


Adjustments to Financial Statements: Removal of Goodwill

Pfizer Inc., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Adjustment to Total Assets
Total assets (as reported)
Less: Goodwill
Total assets (adjusted)
Adjustment to Total Pfizer Inc. Shareholders’ Equity
Total Pfizer Inc. shareholders’ equity (as reported)
Less: Goodwill
Total Pfizer Inc. shareholders’ equity (adjusted)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An examination of the financial information reveals significant adjustments to total assets and shareholders’ equity related to the removal of goodwill and intangible assets. Reported total assets increased from 2021 to 2023, peaking at US$226.501 billion, before declining in 2024 and 2025 to US$213.396 billion and US$208.160 billion, respectively. However, adjusted total assets demonstrate a more moderate growth pattern, increasing from US$132.268 billion in 2021 to US$158.718 billion in 2023, followed by a decrease to US$144.869 billion in 2024 and US$136.896 billion in 2025.

A substantial difference exists between reported and adjusted shareholders’ equity. Reported shareholders’ equity increased considerably from 2021 to 2022, reaching US$95.661 billion, then decreased in subsequent years to US$86.476 billion in 2025. Conversely, adjusted shareholders’ equity shows a more volatile pattern, increasing from US$27.993 billion in 2021 to US$44.286 billion in 2022, then declining sharply to US$15.212 billion by 2025.

Asset Adjustment Impact
The difference between reported and adjusted total assets widens from US$49.208 billion in 2021 to US$67.787 billion in 2023, indicating a growing impact from the removal of goodwill and intangibles. This difference then decreases as reported assets decline faster than adjusted assets in 2024 and 2025, falling to US$68.521 billion in 2024 and US$71.264 billion in 2025.
Shareholders’ Equity Adjustment Impact
The disparity between reported and adjusted shareholders’ equity is even more pronounced. The adjustment reduces shareholders’ equity by US$49.208 billion in 2021, US$51.375 billion in 2022, US$67.783 billion in 2023, US$68.527 billion in 2024, and US$71.264 billion in 2025. This suggests a significant portion of previously reported equity was attributable to goodwill and intangible assets that have been removed through adjustments.

The consistent and substantial reduction in adjusted shareholders’ equity, coupled with the decreasing adjusted total assets, suggests a systematic removal of goodwill and intangible assets from the balance sheet. This could be due to impairment charges or other accounting adjustments. The magnitude of these adjustments warrants further investigation to understand the underlying reasons and their potential impact on the company’s financial position and future performance.


Pfizer Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Goodwill (Summary)

Pfizer Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial metrics demonstrate a significant impact from adjusting for goodwill and intangible assets. Generally, the adjusted ratios reveal a markedly different financial picture compared to the reported figures, particularly concerning profitability and leverage. A consistent pattern emerges where adjustments increase both asset turnover and, more substantially, leverage, while also impacting returns on equity and assets.

Total Asset Turnover
Reported total asset turnover initially increased from 0.45 in 2021 to 0.51 in 2022, before declining to 0.26 in 2023 and stabilizing at 0.30 for 2024 and 2025. The adjusted total asset turnover exhibits a similar trend, rising from 0.62 to 0.69, then falling to 0.38 in 2023, and increasing to 0.44 and 0.46 in the subsequent years. The adjusted ratio consistently exceeds the reported ratio, indicating that excluding goodwill improves the efficiency with which assets generate sales.
Financial Leverage
Reported financial leverage decreased from 2.35 in 2021 to 2.06 in 2022, then increased to 2.54 in 2023, and remained relatively stable at 2.42 and 2.41 for 2024 and 2025. In contrast, adjusted financial leverage shows a substantial increase over the period, moving from 4.73 in 2021 to 3.29 in 2022, then surging to 7.48 in 2023, and continuing to rise to 7.36 and 9.00 in 2024 and 2025. This suggests that the presence of goodwill significantly understates the company’s actual leverage position.
Return on Equity (ROE)
Reported ROE experienced a peak in 2022 at 32.79%, followed by a dramatic decline to 2.38% in 2023, and a modest recovery to 8.99% and 9.11% in 2024 and 2025. The adjusted ROE demonstrates a much higher level of profitability, starting at 78.52% in 2021 and decreasing to 70.84% in 2022, then falling to 9.98% in 2023, before increasing significantly to 40.82% and 51.08% in 2024 and 2025. The substantial difference between reported and adjusted ROE highlights the considerable impact of goodwill on reported earnings.
Return on Assets (ROA)
Reported ROA followed a similar pattern to ROE, with a high of 15.91% in 2022, a sharp decrease to 0.94% in 2023, and a slight recovery to 3.73% and 3.76% in 2024 and 2025. Adjusted ROA also shows an increase from 16.62% in 2021 to 21.51% in 2022, a decline to 1.34% in 2023, and a subsequent increase to 5.54% and 5.68% in 2024 and 2025. As with ROE, the adjusted ROA is consistently higher, indicating that the exclusion of goodwill results in a more favorable assessment of asset profitability.

The year 2023 appears to be an outlier, with particularly low reported values across all profitability ratios. This suggests a potential event or accounting adjustment in that year that significantly impacted reported earnings. The increasing trend in adjusted financial leverage from 2023 to 2025 warrants further investigation, as it indicates a growing reliance on debt when goodwill is excluded from the asset base.


Pfizer Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Revenues
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Revenues
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Total asset turnover = Revenues ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= ÷ =


An examination of the financial information reveals trends in both total asset values and associated turnover ratios over a five-year period. Reported total assets increased from 2021 to 2023, peaking at US$226,501 million, before declining in both 2024 and 2025 to US$208,160 million. Adjusted total assets followed a similar pattern, increasing from US$132,268 million in 2021 to US$158,718 million in 2023, and subsequently decreasing to US$136,896 million in 2025. The adjusted total asset figures are consistently lower than the reported total asset figures across all periods, suggesting a significant portion of the reported assets are comprised of goodwill and intangible assets that are excluded from the adjusted calculation.

Reported Total Asset Turnover
The reported total asset turnover ratio exhibited an initial increase from 0.45 in 2021 to 0.51 in 2022. However, this was followed by a substantial decrease to 0.26 in 2023. A slight recovery to 0.30 was observed in both 2024 and 2025, indicating a stabilization at a lower level of asset utilization compared to the earlier period. This suggests a diminishing ability to generate sales revenue from the reported asset base.
Adjusted Total Asset Turnover
The adjusted total asset turnover ratio also increased from 0.62 in 2021 to 0.69 in 2022, demonstrating improved efficiency in utilizing adjusted assets. Similar to the reported ratio, a decline was observed in 2023, falling to 0.38. The ratio then increased to 0.44 in 2024 and further to 0.46 in 2025, indicating a gradual improvement in asset utilization after the 2023 dip. The adjusted turnover ratio consistently exceeds the reported turnover ratio, highlighting the impact of goodwill and intangible assets on the overall reported asset turnover.

The divergence between the reported and adjusted asset turnover ratios underscores the importance of considering the composition of assets when evaluating operational efficiency. The decline in both ratios in 2023, followed by a partial recovery in subsequent years, warrants further investigation to understand the underlying drivers of these changes. The stabilization of both ratios in 2024 and 2025 suggests a potential plateau in asset utilization efficiency.


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total Pfizer Inc. shareholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total Pfizer Inc. shareholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Financial leverage = Total assets ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Pfizer Inc. shareholders’ equity
= ÷ =


An examination of the financial information reveals significant trends in both reported and adjusted financial leverage over the five-year period. Reported total assets increased from 2021 to 2023, then decreased in 2024 and 2025. A similar pattern is observed in reported total shareholders’ equity, peaking in 2022 and declining thereafter. However, the adjusted figures present a markedly different picture, particularly concerning shareholders’ equity and the resulting leverage calculations.

Adjusted Financial Leverage
Adjusted financial leverage demonstrates a substantial increase throughout the period. Starting at 4.73 in 2021, it rose to 9.00 in 2025. This indicates a growing reliance on debt relative to adjusted equity. The increase is particularly pronounced between 2023 and 2025, accelerating from 7.48 to 9.00. This trend contrasts sharply with the relatively stable reported financial leverage.
Adjusted vs. Reported Assets
The difference between reported and adjusted total assets is considerable. Adjusted total assets are consistently lower than reported total assets, suggesting a significant portion of the reported asset base is comprised of items excluded in the adjusted calculation, likely goodwill and intangible assets. The gap between the two asset figures appears to widen slightly over time, indicating a growing proportion of these excluded assets.
Adjusted vs. Reported Equity
The disparity between reported and adjusted shareholders’ equity is even more striking. Adjusted shareholders’ equity is substantially lower than reported equity, and exhibits greater volatility. The decline in adjusted equity from 2022 to 2025 is particularly noteworthy, contributing significantly to the increase in adjusted financial leverage. This suggests that the adjustments made to equity remove components that are considered less reliable or sustainable.

Reported financial leverage remains relatively stable, fluctuating between 2.06 and 2.54. However, the increasing adjusted financial leverage suggests a potentially heightened risk profile when considering a more conservative view of the company’s capital structure. The divergence between the reported and adjusted figures warrants further investigation into the nature of the adjustments made to both assets and equity.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Pfizer Inc. common shareholders
Total Pfizer Inc. shareholders’ equity
Profitability Ratio
ROE1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Net income attributable to Pfizer Inc. common shareholders
Adjusted total Pfizer Inc. shareholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROE = 100 × Net income attributable to Pfizer Inc. common shareholders ÷ Total Pfizer Inc. shareholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Net income attributable to Pfizer Inc. common shareholders ÷ Adjusted total Pfizer Inc. shareholders’ equity
= 100 × ÷ =


Analysis reveals significant divergence between reported and adjusted return on equity (ROE) figures over the five-year period. Shareholders’ equity, both reported and adjusted, demonstrates fluctuating trends. The reported ROE exhibits considerable volatility, while the adjusted ROE shows a more pronounced shift in performance beginning in 2023.

Shareholders’ Equity Trends
Reported total shareholders’ equity increased from US$77.201 billion in 2021 to US$95.661 billion in 2022, before declining to US$86.476 billion by 2025. This suggests initial growth followed by a contraction in reported equity. Adjusted total shareholders’ equity experienced a more dramatic fluctuation, rising sharply to US$44.286 billion in 2022, then decreasing substantially to US$15.212 billion in 2025. The magnitude of the decrease in adjusted equity is considerably larger than that of the reported equity.
Reported ROE Analysis
Reported ROE peaked at 32.79% in 2022, following 28.47% in 2021, and then experienced a substantial decline to 2.38% in 2023. A partial recovery was observed in 2024 (9.11%) and 2025 (8.99%), but remained significantly below the 2022 high. This pattern indicates a period of strong profitability followed by a marked reduction, with limited subsequent improvement.
Adjusted ROE Analysis
Adjusted ROE began at a high of 78.52% in 2021, decreased to 70.84% in 2022, and then fell sharply to 9.98% in 2023. A substantial increase is then observed, with adjusted ROE reaching 40.82% in 2024 and further increasing to 51.08% in 2025. This suggests that adjustments to shareholders’ equity significantly impact the perceived return on equity, and that underlying performance, as reflected in the adjusted figures, improved considerably in the latter part of the period despite the decline in adjusted equity.

The considerable difference between reported and adjusted ROE values, particularly from 2023 onwards, warrants further investigation into the nature of the adjustments made to shareholders’ equity. The contrasting trends suggest that items impacting reported equity do not necessarily align with those affecting the adjusted calculation, and that the adjustments are having a material effect on the assessment of profitability.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Pfizer Inc. common shareholders
Total assets
Profitability Ratio
ROA1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Net income attributable to Pfizer Inc. common shareholders
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net income attributable to Pfizer Inc. common shareholders ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Net income attributable to Pfizer Inc. common shareholders ÷ Adjusted total assets
= 100 × ÷ =


An examination of the financial information reveals distinct trends in both reported and adjusted total assets, as well as their corresponding returns on assets. Reported total assets increased from 2021 to 2023, peaking at US$226,501 million, before declining in both 2024 and 2025 to US$213,396 million and US$208,160 million, respectively. Adjusted total assets followed a similar pattern, increasing from US$132,268 million in 2021 to US$158,718 million in 2023, and then decreasing to US$144,869 million in 2024 and US$136,896 million in 2025. The difference between reported and adjusted total assets suggests the presence of significant goodwill and intangible assets impacting the reported figures.

Reported Return on Assets (ROA)
Reported ROA exhibited a rise from 12.11% in 2021 to a peak of 15.91% in 2022. However, a substantial decrease was observed in 2023, falling to 0.94%. A modest recovery occurred in 2024 and 2025, with ROA reaching 3.76% and 3.73% respectively, indicating a stabilization at a lower level compared to prior years. This volatility suggests the reported earnings are sensitive to changes in the total asset base, potentially due to the inclusion of items subject to impairment or amortization.
Adjusted Return on Assets (ROA)
Adjusted ROA also increased from 2021 to 2022, moving from 16.62% to 21.51%. Similar to the reported ROA, a significant decline occurred in 2023, with the adjusted ROA dropping to 1.34%. A subsequent increase was noted in 2024 and 2025, reaching 5.54% and 5.68% respectively. The adjusted ROA consistently exceeded the reported ROA across all periods, indicating that the exclusion of certain asset items results in a more favorable return metric. The pattern of decline and subsequent recovery mirrors that of the reported ROA, suggesting underlying operational factors are influencing profitability.

The convergence of the reported and adjusted ROA trends in 2024 and 2025, despite remaining disparate, suggests that the impact of the adjustments to total assets may be lessening in relative terms. The substantial declines in both reported and adjusted ROA in 2023 warrant further investigation to determine the underlying causes, potentially related to increased costs, decreased revenues, or asset write-downs. The consistent difference between the two ROA figures highlights the importance of understanding the composition of the asset base and the potential impact of goodwill and intangible assets on overall financial performance.